Solu-Medrol (methylprednisolone sodium succinate) — HCPCS J2919

Methylprednisolone class — Solu-Medrol (J2919) vs Depo-Medrol (J1020 / J1030 / J1040) CMS HCPCS verified May 2026

Same active drug, two different salts. Wrong J-code or wrong route is a denial trigger and can cause patient harm.

Methylprednisolone is supplied in two completely separate billable salts: methylprednisolone sodium succinate (Solu-Medrol, water-soluble, for IV or IM, J2919) and methylprednisolone acetate (Depo-Medrol, insoluble depot suspension, for IM and intra-articular only — NEVER IV, J1020/J1030/J1040 depending on dose). They share the parent corticosteroid but cannot be interchanged at the bedside or on the claim form.

Dosing & unit math FDA label verified May 2026

From the FDA-approved Pfizer Solu-Medrol prescribing information. Indications span MS, transplant, allergy, pulmonary, oncology premedication, and severe autoimmune disease.

Multi-indication dosing matrix

Dose-to-J-code unit math (the #1 biller error)

J2919 unit basis is 5 mg = 1 unit. Most chemo HCPCS codes use 1 mg or 10 mg per unit, and muscle memory leads billers to enter the milligram value directly — producing 25× overbilling on a 125 mg dose. Cross-check every J2919 line: units = mg / 5.

Worked example — MS pulse course (1 g IV daily × 5 days)

Worked example — oncology premed (125 mg IV push before paclitaxel)

Vial selection & waste posture

Solu-Medrol comes in many vial sizes (40 mg, 125 mg, 500 mg, 1 g, 2 g) and the branded Pfizer Act-O-Vial contains integrated diluent. Choose the vial size that minimizes waste for the ordered dose:

• 125 mg dose → use the 125 mg vial (no waste, JZ modifier)
• 40 mg dose → use the 40 mg vial (no waste, JZ modifier)
• 1 g MS pulse → use the 1 g vial (no waste, JZ modifier)
• 250 mg dose → use two 125 mg vials, or one 500 mg vial with 250 mg discarded (JW)

Because vial sizes are tightly matched to common doses, JW waste is much less common with Solu-Medrol than with BSA-dosed oncology agents. JZ is the more frequent modifier.

NDC reference FDA NDC Directory verified May 2026

HCPCS J2919 is a NOS code covering branded Pfizer Solu-Medrol and all generic methylprednisolone sodium succinate. The NDC on the claim line identifies the specific product dispensed; the J-code and per-5-mg unit math are identical.

Administration codes CPT verified May 2026

Solu-Medrol is a corticosteroid — NOT cytotoxic chemotherapy and NOT a biologic response modifier. Therapeutic IV admin CPT codes apply, never chemo admin.

Modifiers CMS verified May 2026

JZ — the more common modifier for Solu-Medrol

Because Solu-Medrol vials are sized closely to common doses (40 mg, 125 mg, 500 mg, 1 g, 2 g) and the drug is not BSA-dosed, the dispensed vial typically matches the ordered dose exactly. JZ ("no discarded amount") applies to most J2919 claims. One of JZ or JW must be on every J2919 claim per CMS's July 2023 single-dose container policy.

JW — when used

JW applies when a vial is opened and a portion is discarded for that patient (e.g., 250 mg dose drawn from a 500 mg vial = 250 mg discarded, JW for 50 units of J2919). Both administered and discarded units pay at ASP+6%. Document the discarded mg in the MAR.

Worked example — JW on a 250 mg dose from a 500 mg vial

Multi-dose vial caveat

Most current Solu-Medrol presentations are single-dose Act-O-Vials. Historical multi-dose vials with preservative existed and may still appear in some generic line extensions. JW/JZ apply only to single-dose containers per CMS policy. For preserved multi-dose vials, no JW/JZ modifier is required — bill only the actual administered units.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion. Routine pre-infusion clinical assessment is bundled into the admin code.

340B modifiers (JG, TB)

For 340B-acquired Solu-Medrol, follow your MAC's current 340B modifier policy. Solu-Medrol is a low-ASP drug; the 340B economic differential per dose is small but reporting remains required for HOPDs.

ICD-10-CM by indication FY2026 verified May 2026

Solu-Medrol's broad indication footprint means ICD-10 selection drives PA approval and denial appeals more than the J-code itself. Document the underlying acute condition; payers will deny on "steroid administration" alone.

Site of care & place of service Verified May 2026

Solu-Medrol is administered across virtually every acute and ambulatory care setting. Site-of-care utilization management on J2919 is rare (the drug cost is small), but admin CPT and POS combinations determine the fee-schedule reimbursement that pays the encounter.

Claim form field mapping CMS-1500 + UB-04 verified May 2026

Standard CMS-1500 fields for office and freestanding settings. UB-04 mapping for HOPD.

Payer policy snapshot Reviewed May 2026

J2919 is rarely subject to PA on the drug itself (it's cheap). PA scrutiny falls on the underlying encounter coding and the MS-pulse outpatient site of care.

Step therapy

No step therapy on the drug itself — J2919 is generic, low-cost, and indicated as first-line for the acute scenarios it's used in. The clinical step is to oral prednisone for routine flare management; Solu-Medrol IV is reserved for acute, severe, or NPO contexts. Some payers will deny J2919 outpatient if documentation supports an equivalent oral regimen.

Medical-necessity documentation expectations

• MS pulse: MRI confirmation of acute exacerbation, lesion location, neurologic exam findings, prior corticosteroid history
• Transplant rejection: biopsy-confirmed acute cellular rejection or clinical rejection with supporting labs (creatinine rise, LFT rise, troponin, etc.)
• Severe asthma: peak flow / FEV1 documentation, prior outpatient steroid course history
• Oncology premed: prior infusion hypersensitivity history or routine pre-medication protocol per chemo regimen

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to methylprednisolone sodium succinate. Coverage falls under MAC LCDs for outpatient infusion services and the generic drug coverage framework. All MACs cover J2919 for medically necessary on-label indications with appropriate ICD-10 and clinical documentation. Off-label use is widely accepted in clinical practice (e.g., spinal cord injury, septic shock adjunct in some protocols) but coverage depends on indication-specific documentation.

Code history

• J2919 — permanent code, "Injection, methylprednisolone sodium succinate, 5 mg"; long-standing assignment with no recent code changes
• Historical legacy codes J2920 (40 mg) and J2930 (125 mg) were deleted years ago; do not use — all current methylpred-sod-succ billing flows through J2919 with 5-mg units

Patient assistance — usually not required Reviewed May 2026

Solu-Medrol is one of the lowest-cost specialty-billed drugs on the catalog. Generic methylprednisolone sodium succinate is widely available and reimburses at ~$0.241 per 5 mg unit under Medicare Part B. A full 5-day MS pulse course of 1 g daily reimburses at roughly $241 in drug cost; a single oncology premed dose is under $10. Patient cost-sharing on a Solu-Medrol line is typically negligible.

When patient assistance can still help

• Pfizer Patient Assistance Program (Pfizer RxPathways): branded Pfizer Solu-Medrol qualifies for Pfizer's general patient assistance program for uninsured/underinsured patients meeting income criteria. Phone: 1-844-989-7284 / pfizerrxpathways.com
• Bundled into infusion-encounter assistance: when Solu-Medrol is given as a premed in an oncology encounter, the chemo agent's manufacturer copay assistance (e.g., BMS Access Support for paclitaxel-related encounters, Genentech Access Solutions for mAb-related encounters) generally absorbs the small premed cost as part of the broader infusion-day OOP calculation
• Hospital charity care: for severe outpatient courses (transplant rejection, vasculitis induction), hospital financial-assistance programs typically cover Solu-Medrol as part of the encounter charity-care eligibility
• Generic typically too cheap to need a program: the vast majority of J2919 administrations do not generate patient OOP that warrants a dedicated copay program

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Solu-Medrol?

Solu-Medrol (methylprednisolone sodium succinate, IV/IM) is billed under HCPCS J2919 — "Injection, methylprednisolone sodium succinate, 5 mg." Every 5 mg administered equals one billable unit. This is a major unit-math trap: a 125 mg dose is 25 units, NOT 125. Cross-check every J2919 line: units = mg / 5.

Is Solu-Medrol billed with chemotherapy admin CPT 96413 when given as an oncology premed?

No. Solu-Medrol is NOT chemotherapy regardless of clinical context. It is a corticosteroid and the correct CPT is 96365 (therapeutic IV infusion, up to 1 hour) for an infusion, or 96374 (therapeutic IV push, single or initial substance) for an IV push of 15 minutes or less. 96413 is reserved for cytotoxic chemotherapy and biologic response modifiers per AMA CPT guidelines, and billing it on a Solu-Medrol line is one of the most common errors on oncology premed claims. The downstream chemo agent bills 96413 as the initial chemo of the encounter; Solu-Medrol bills 96365/96374 as a standalone admin or 96367/96375 as a sequential add-on after the chemo. See the administration codes section for the full CPT hierarchy rule.

How do I calculate units for Solu-Medrol dose-to-J-code math?

J2919 unit basis is 5 mg = 1 unit. Common doses: 40 mg = 8 units, 80 mg = 16 units, 125 mg = 25 units, 250 mg = 50 units, 500 mg = 100 units, 1,000 mg (1 g) = 200 units. An MS pulse-dose course of 1 g IV daily for 3–5 days is a high unit-count claim — 200 units per day × 5 days = 1,000 units of J2919 over the course. Bill the actual mg administered ÷ 5.

How is Solu-Medrol (J2919) different from Depo-Medrol (J1020 / J1030 / J1040)?

Different salts, different routes, different J-codes. Solu-Medrol is methylprednisolone sodium succinate — water-soluble, used IV or IM for rapid systemic effect (J2919, 5 mg = 1 unit). Depo-Medrol is methylprednisolone acetate — insoluble depot suspension, used IM or intra-articular for prolonged local effect, NEVER IV (J1020 20 mg, J1030 40 mg, J1040 80 mg per unit). Do not interchange — the wrong J-code is a denial trigger and the wrong route can cause embolism with Depo-Medrol. See the Solu-Medrol vs Depo-Medrol comparison table.

What is the right CPT for an MS pulse dose of 1 g Solu-Medrol IV?

96365 (therapeutic IV infusion, up to 1 hour) for the 30–60 minute infusion typical of an MS pulse dose, plus J2919 × 200 units for the 1 g of methylprednisolone. If the infusion extends beyond 60 minutes (rare for pulse dosing), add 96366 for each additional hour. Document MRI-confirmed acute exacerbation, lesion location, and neurologic exam findings — payer audits and PA renewals routinely request MS pulse-dose medical-necessity documentation.

When do I bill 96365 vs 96374 for Solu-Medrol?

Use 96365 (therapeutic IV infusion, up to 1 hour) when Solu-Medrol is administered as an infusion — typically piggyback or dilute over 16–60 minutes (standard for doses 125 mg and above). Use 96374 (therapeutic IV push, single or initial substance) when administered as a slow push over 3–15 minutes — common for lower doses (40–125 mg) in oncology premed or ED/ICU settings. Documentation must show actual infusion duration; under-15-minute infusions billed as 96365 are commonly downcoded to 96374 on audit.

Do I bill the branded Pfizer Solu-Medrol differently from generic methylprednisolone sodium succinate?

No — HCPCS J2919 is the NOS (not otherwise specified) code that covers both Pfizer's branded Solu-Medrol and all generic methylprednisolone sodium succinate from Hospira (Pfizer), Sandoz, Fresenius Kabi, X-Gen, Mylan, and others. The NDC on the claim line identifies the specific product dispensed, but the J-code and per-5-mg unit math are identical. Most sites use generic; ASP+6% reimbursement for J2919 reflects the weighted-average ASP across all reporting manufacturers.

What is the Medicare reimbursement for J2919?

For Q2 2026, the Medicare Part B payment limit for J2919 is $0.241 per 5 mg unit (ASP + 6%). Per-dose reimbursement examples: 40 mg ~ $1.93, 125 mg ~ $6.03, 250 mg ~ $12.05, 500 mg ~ $24.10, 1 g (200 units) ~ $48.20. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. The drug cost is small; the administration CPT and the underlying encounter typically drive the larger reimbursement on a Solu-Medrol claim.

What ICD-10 codes do I use for Solu-Medrol?

Indication-specific and broad. Multiple sclerosis exacerbation: G35. Transplant rejection: T86.x (organ-specific: T86.11 kidney, T86.41 liver, T86.21 heart, T86.810 lung). Asthma exacerbation: J45.x (severity-specific). Severe allergic reaction: T78.0xxA, T78.2xxA (anaphylaxis), T78.40xA. COPD exacerbation: J44.1. Severe dermatologic flare: L10.x, L51.x. RA flare: M05.x / M06.x. Severe vasculitis: M31.x / M30.x. Document the underlying acute indication, not "steroid administration" alone — payers will deny on insufficient diagnosis coding.

Source documents

1. Pfizer — SOLU-MEDROL (methylprednisolone sodium succinate) prescribing information
   FDA-approved label; full prescribing information including indications, dosing, warnings & precautions
2. DailyMed — methylprednisolone sodium succinate (Solu-Medrol & generics)
   Current FDA labels, NDCs, package inserts for branded and generic products
3. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
4. CMS HCPCS Level II Quarterly Updates
   J2919 descriptor and unit basis verification
5. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose container waste reporting requirement — one of JZ/JW required on every J2919 claim
6. American Academy of Neurology — Multiple Sclerosis guidelines
   High-dose IV methylprednisolone (1 g daily × 3–5 days) for acute MS exacerbation
7. NCCN Clinical Practice Guidelines in Oncology — Supportive Care (Hypersensitivity Reactions)
   Corticosteroid premedication regimens for taxane/mAb infusions
8. GINA — Global Initiative for Asthma management strategy
   Systemic corticosteroid use in severe asthma exacerbation
9. GOLD — Global Initiative for Chronic Obstructive Lung Disease
   Systemic corticosteroid use in COPD exacerbation
10. American Society of Transplantation — Acute Rejection management
    Pulse IV methylprednisolone for acute cellular rejection across solid-organ transplant
11. FDA National Drug Code Directory
    NDC verification for branded Solu-Medrol and generic methylprednisolone sodium succinate
12. AMA CPT — Infusion and chemotherapy administration coding hierarchy
    96365 / 96374 (non-chemo) vs 96413 (chemo) admin code selection rules

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication. ASP data: Q2 2026. Manufacturer source: Pfizer Solu-Medrol PI 2026 + generic NDC verification. Multi-indication coverage (MS pulse, oncology premed, transplant rejection, asthma, COPD, anaphylaxis, autoimmune flare). Depo-Medrol comparison included. Explicit anti-pattern callout: NOT chemo, NOT 96413 admin CPT.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list and dosing are verified against the current Pfizer FDA label. Society-guideline references (AAN for MS, NCCN for premedication, GINA for asthma, GOLD for COPD) document acute-care use patterns. We do not paraphrase from billing-software vendor blogs.